SEC Form 4
Johnson & Johnson (JNJ) insider trading
In the 12 months to Oct 23, 2026, 10 JNJ insiders reported open-market sales of $150.7M across 15 filings; one director bought $257.7K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $150.7M
- 15 filings · 10 insiders
- Open-market purchases
- $257.7K
- 1 filing · John G. Morikis, Director
Who traded JNJ, and when
- Purchase
- Sale
JNJ daily close from Oct 23, 2025 to Oct 23, 2026, between $186.00 and $278.43, last $263.81. 15 sale and 1 purchase filings by 11 insiders, marked at their filing dates. Joaquin Duato, CEO and Chairman of the Board: sold $66.8M across 3 filings, first filed Jan 28, 2026, last Aug 14, 2026. Joseph J. Wolk, Exec VP, CFO: sold $21.8M across 1 filing, first filed Feb 18, 2026, last Feb 18, 2026. James D. Swanson, EVP, CIO: sold $15.1M across 1 filing, first filed Feb 18, 2026, last Feb 18, 2026. Timothy Schmid, EVP, WW Chair, MedTech: sold $15.1M across 3 filings, first filed Feb 18, 2026, last Sep 4, 2026. John C. Reed, EVP, Innovative Medicine, R&D: sold $13.1M across 1 filing, first filed Feb 18, 2026, last Feb 18, 2026. Vanessa Broadhurst, EVP, Global Corp Affairs: sold $7.3M across 2 filings, first filed Feb 18, 2026, last Jul 21, 2026. John G. Morikis, Director: bought $257.7K across 1 filing, first filed Dec 1, 2025, last Dec 1, 2025. 4 others: sold $11.5M across 4 filings, first filed Mar 3, 2026, last Aug 18, 2026.
Largest mark · tap a row for others
Joaquin Duato · CEO and Chairman of the Board
Sale $32,199,927
123,291 shares at $261.17 avg
Filed Aug 14, 2026 · traded Aug 13
Close on filing date $260.35
Joaquin Duato · CEO and Chairman of the Board
CEO and Chairman of the Board
$66.8M soldJoseph J. Wolk · Exec VP, CFO
Exec VP, CFO
$21.8M soldJames D. Swanson · EVP, CIO
EVP, CIO
$15.1M soldTimothy Schmid · EVP, WW Chair, MedTech
EVP, WW Chair, MedTech
$15.1M soldJohn C. Reed · EVP, Innovative Medicine, R&D
EVP, Innovative Medicine, R&D
$13.1M soldVanessa Broadhurst · EVP, Global Corp Affairs
EVP, Global Corp Affairs
$7.3M soldJohn G. Morikis · Director
Director
$257.7K bought4 others
Combined, one mark per week
$11.5M soldHas Johnson & Johnson's CEO sold stock?
Yes. Joaquin Duato (CEO) sold 271,771 shares ($66.8M) between Jan 2026 and Aug 2026.
Open-market trades
16 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Joaquin Duato | CEO and Chairman of the Board | $66.8M | — | 3 | — | |
| Joseph J. Wolk | Exec VP, CFO | $21.8M | — | 1 | — | |
| James D. Swanson | EVP, CIO | $15.1M | — | 1 | — | |
| Timothy Schmid | EVP, WW Chair, MedTech | $15.1M | — | 3 | — | |
| John C. Reed | EVP, Innovative Medicine, R&D | $13.1M | — | 1 | — | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | $7.3M | — | 2 | — | |
| Elizabeth Forminard | EVP, Chief Legal Officer | $4.1M | — | 1 | — | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | $4.0M | — | 1 | — | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | $2.4M | — | 1 | — | |
| Robert J. Decker | VP Corporate Controller | $1.0M | — | 1 | — | |
| John G. Morikis | Director | — | $257.7K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Timothy Schmid EVP, WW Chair, MedTech | Sale | 33,597 | $274.74 | $9.2M | 25,447 | |
traded | Jennifer L. Taubert EVP, WWC. Innovative Medicine | Sale | 15,000 | $263.36 | $4.0M | 194,451 | |
traded | Joaquin Duato CEO and Chairman of the Board | Sale | 123,291 | $261.17 | $32.2M | 275,967 | |
traded | Elizabeth Forminard EVP, Chief Legal Officer | Sale | 15,918 | $257.00 | $4.1M | 16,994 | |
traded | Joaquin Duato CEO and Chairman of the Board | Sale | 48,480 | $258.15 | $12.5M | 275,967 | |
traded | Vanessa Broadhurst EVP, Global Corp Affairs | Sale | 23,054 | $251.27 | $5.8M | 23,003 | |
traded | Kathryn E. Wengel EVP, Chief TO and Risk Officer | Sale | 10,000 | $241.15 | $2.4M | 114,288 | |
traded | Robert J. Decker VP Corporate Controller | Sale | 4,075 | $247.87 | $1.0M | 23,682 | |
traded | Timothy Schmid EVP, WW Chair, MedTech | Sale | 1,322 | $245.66 | $324.8K | 25,447 | |
traded | Vanessa Broadhurst EVP, Global Corp Affairs | Sale | 6,197 | $243.39 | $1.5M | 23,003 | |
traded | Timothy Schmid EVP, WW Chair, MedTech | Sale | 22,623 | $244.33 | $5.5M | 26,769 | |
traded | John C. Reed EVP, Innovative Medicine, R&D | Sale | 53,931 | $243.00 | $13.1M | 10,658 | |
traded | Joseph J. Wolk Exec VP, CFO | Sale | 89,654 | $242.80 | $21.8M | 14,000 | |
traded | James D. Swanson EVP, CIO | Sale | 62,080 | $243.39 | $15.1M | 25,698 | |
traded | Joaquin Duato CEO and Chairman of the Board | Sale | 100,000 | $221.23 | $22.1M | 30,852 | |
traded | John G. Morikis Director | Purchase | 1,250 | $206.15 | $257.7K | 1,849 |
GET /stocks/filings/vX/form-4?tickers=JNJ&filing_date.gte=2025-10-23&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"JNJ",
"JNJ.WD"
],
"issuer_cik": "0000200406",
"owner_cik": "0001998491",
"accession_number": "0000200406-26-000179",
"form_type": "4",
"filing_date": "2026-09-04",
"period_of_report": "2026-09-02",
"issuer_name": "JOHNSON & JOHNSON",
"issuer_trading_symbol": "JNJ",
"owner_name": "Schmid Timothy",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, WW Chair, MedTech",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 11070,
"transaction_price_per_share": 274.74,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 25447,
"transaction_value": 3041371.8000000003,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
},
{
"tickers": [
"JNJ",
"JNJ.WD"
],
"issuer_cik": "0000200406",
"owner_cik": "0001998491",
"accession_number": "0000200406-26-000179",
"form_type": "4",
"filing_date": "2026-09-04",
"period_of_report": "2026-09-02",
"issuer_name": "JOHNSON & JOHNSON",
"issuer_trading_symbol": "JNJ",
"owner_name": "Schmid Timothy",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, WW Chair, MedTech",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 22527,
"transaction_price_per_share": 274.74,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 25447,
"transaction_value": 6189067.98,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 113 records
- Option exercises66 records
- Tax withholding47 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for JNJ every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.